Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor monotherapy in JAK inhibitor-naive myelofibrosis with moderate thrombocytopenia
2024-511309-47-00Phase 2Authorised
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label, single-arm trial of selinexor in myelofibrosis (MF), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Proportion of patients with spleen volume reduction of at least 35% at Week 24. Planned start Jul 2024; status: authorised.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2024-511309-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511309-47-00.